STRUCTURE THERAPEUTICS INC

GPCRNASDAQ

🏆 #1278 by market capEarnings Nov 4 · PostUS Equity

$554.43▲ $44.63 (+8.05%)

Simulated price

1h—

24h▲ 8.1%

7d—

14d—

30d—

1y—

🏦Market Cap

$3.83B

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Fair

No chart data available for GPCR.

Trading Snapshot

Day Range: $551.44 – $563.88
52-Week Range: $15.86 – $94.90
Volume: $7.77B
Avg Volume: $10.30B
Shares Outstanding: 213.2M
Next Earnings: Sep 7, 2026

Fundamentals Snapshot

Annual Revenue: $958M
Last Q Revenue: $254M
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-0.91
Dividend Yield: —

Why Investors Own GPCR

✓High-growth profile — revenue up +43.0% YoY with expanding US Equity exposure.
✓Healthy economics — 38% gross margin and 27% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$958M▲ +43.0% YoY

Gross Margin (TTM)

38.4%▲ +4.5% YoY

Operating Income (TTM)

$330M▲ +43.0% YoY

Free Cash Flow (TTM)

$254M▲ +43.0% YoY

About STRUCTURE THERAPEUTICS INC

Structure Therapeutics Inc., an international biopharmaceutical company currently in its clinical development phase, is committed to creating and providing groundbreaking oral therapies for various chronic diseases that lack adequate treatment options. The company's primary investigational drug, GSBR-1290, is an orally administered, biased small molecule agonist designed to target the glucagon-like-peptide-1 receptor (GLP-1R). This G-protein-coupled receptor (GPCR) is a recognized and validated therapeutic target for managing both type-2 diabetes mellitus and obesity. Furthermore, Structure Therapeutics is developing other oral small molecule treatments that act on different GPCRs, addressing pulmonary and cardiovascular conditions. For example, ANPA-0073 is a biased agonist aimed at the apelin receptor, a GPCR linked to diseases like idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension. Another compound in their pipeline is LTSE-2578, an oral small molecule that acts as a lysophosphatidic acid 1 receptor antagonist, also being explored for the treatment of IPF. Established in 2016, the company was formerly known as ShouTi Inc. and is headquartered in South San Francisco, California.

🦦